JP2023511403A5 - - Google Patents
Info
- Publication number
- JP2023511403A5 JP2023511403A5 JP2022544649A JP2022544649A JP2023511403A5 JP 2023511403 A5 JP2023511403 A5 JP 2023511403A5 JP 2022544649 A JP2022544649 A JP 2022544649A JP 2022544649 A JP2022544649 A JP 2022544649A JP 2023511403 A5 JP2023511403 A5 JP 2023511403A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody
- antibody fragment
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964747P | 2020-01-23 | 2020-01-23 | |
| US62/964,747 | 2020-01-23 | ||
| PCT/US2021/014790 WO2021151020A1 (en) | 2020-01-23 | 2021-01-22 | Conditionally active anti-her2 antibodies, antibody fragments their immunoconjugates and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023511403A JP2023511403A (ja) | 2023-03-17 |
| JP2023511403A5 true JP2023511403A5 (enExample) | 2024-01-19 |
| JP7856312B2 JP7856312B2 (ja) | 2026-05-11 |
Family
ID=76992835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544649A Active JP7856312B2 (ja) | 2020-01-23 | 2021-01-22 | 条件的に活性な抗ｈｅｒ２抗体、抗体断片、それらの免疫コンジュゲート、およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230109218A1 (enExample) |
| EP (1) | EP4093774A4 (enExample) |
| JP (1) | JP7856312B2 (enExample) |
| KR (1) | KR20220131937A (enExample) |
| CN (1) | CN115943164A (enExample) |
| AU (1) | AU2021210412A1 (enExample) |
| CA (1) | CA3165662A1 (enExample) |
| IL (1) | IL294829A (enExample) |
| MX (1) | MX2022009138A (enExample) |
| TW (1) | TW202140559A (enExample) |
| WO (1) | WO2021151020A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115485293A (zh) * | 2020-01-23 | 2022-12-16 | 埃克苏马生物技术公司 | 用于her2的嵌合抗原受体和其使用方法 |
| TW202532440A (zh) | 2023-10-19 | 2025-08-16 | 美商建南德克公司 | 用於治療ＨＥＲ２陽性癌症的ＩＬ１５／ＩＬ１５Ｒα異二聚體ＦＣ融合蛋白及ＨＥＲ２ｘＣＤ３雙特異性抗體之組合 |
| KR20250175725A (ko) * | 2024-06-07 | 2025-12-17 | (주)지아이이노베이션 | Cd80 단백질 및 il-2 단백질을 포함하는 융합단백질 및 항체-약물 접합체를 포함하는 암 치료용 약학 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005522514A (ja) | 2002-04-10 | 2005-07-28 | ジェネンテック・インコーポレーテッド | 抗ｈｅｒ２抗体改変体 |
| US8236308B2 (en) * | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| EP2513148B1 (en) * | 2009-12-16 | 2016-08-31 | AbbVie Biotherapeutics Inc. | Anti-her2 antibodies and their uses |
| WO2014052713A2 (en) * | 2012-09-27 | 2014-04-03 | Massachusetts Institute Of Technology | Her2-and vegf-a-binding proteins with enhanced stability |
| PT3480215T (pt) * | 2013-11-19 | 2021-07-05 | Remegen Ltd | Anticorpo anti-her2 e seu conjugado |
| ES2763429T5 (es) * | 2013-12-17 | 2023-06-21 | Hoffmann La Roche | Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos |
| JP6510532B2 (ja) * | 2013-12-20 | 2019-05-08 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性ｈｅｒ２抗体及び使用方法 |
| RU2689145C2 (ru) * | 2014-04-16 | 2019-05-24 | Биокон Лтд. | Стабильные белковые препараты, содержащие молярный избыток сорбитола |
| WO2015164723A1 (en) | 2014-04-25 | 2015-10-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
| ES3043088T3 (en) | 2015-06-17 | 2025-11-24 | Hoffmann La Roche | Anti-her2 antibodies and methods of use |
| EP3740505A1 (en) * | 2018-01-16 | 2020-11-25 | Lakepharma Inc. | Bispecific antibody that binds cd3 and another target |
| CN112513081A (zh) | 2018-06-14 | 2021-03-16 | 生物蛋白有限公司 | 多重特异性抗体构建体 |
-
2021
- 2021-01-22 KR KR1020227026938A patent/KR20220131937A/ko active Pending
- 2021-01-22 AU AU2021210412A patent/AU2021210412A1/en active Pending
- 2021-01-22 MX MX2022009138A patent/MX2022009138A/es unknown
- 2021-01-22 TW TW110102594A patent/TW202140559A/zh unknown
- 2021-01-22 CA CA3165662A patent/CA3165662A1/en active Pending
- 2021-01-22 JP JP2022544649A patent/JP7856312B2/ja active Active
- 2021-01-22 US US17/759,195 patent/US20230109218A1/en active Pending
- 2021-01-22 EP EP21744106.2A patent/EP4093774A4/en active Pending
- 2021-01-22 WO PCT/US2021/014790 patent/WO2021151020A1/en not_active Ceased
- 2021-01-22 CN CN202180012021.3A patent/CN115943164A/zh active Pending
- 2021-01-22 IL IL294829A patent/IL294829A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023531185A5 (enExample) | ||
| JP2018520991A5 (enExample) | ||
| TWI787796B (zh) | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 | |
| JP2018520091A5 (enExample) | ||
| JP2022522344A5 (enExample) | ||
| JP2022515318A5 (enExample) | ||
| IL291545B1 (en) | Anti-CTLA4 antibodies, antibody fragments, immunoconjugates thereof and uses thereof | |
| JP2022101693A5 (enExample) | ||
| HRP20241417T1 (hr) | Bifunkcionalno antitijelo anti-pd-1 i anti-vegfa, njegov farmaceutski pripravak i njegova uporaba | |
| Hong et al. | Chemoenzymatic synthesis of a rhamnose‐functionalized bispecific nanobody as a bispecific antibody mimic for cancer immunotherapy | |
| JP2018520092A5 (enExample) | ||
| JP2020531043A5 (enExample) | ||
| JP2020529864A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| CA2595610A1 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| JP2023507190A5 (enExample) | ||
| CN117946277A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2020526584A5 (enExample) | ||
| RU2010116256A (ru) | Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста | |
| JP2024542192A5 (enExample) | ||
| JP2025507817A5 (enExample) | ||
| JP2019524640A5 (enExample) | ||
| JP2022512672A5 (enExample) | ||
| TW202144377A (zh) | 用於分子接合或工程化的縱排重複癌症靶向胜肽及其於癌症診療中的用途 | |
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 |